Moleculin 10-Q: $7.3M Cash, Going Concern Doubt, Nasdaq Exception to March 15, 2027
MBRX has more than doubled off its 52-week low of $3.228 on light trading volume (0.2× avg).
Summary
Moleculin reported $7.3 million of cash at September 30, 2026, said that is not enough to fund a year of operations, and disclosed a new Nasdaq panel exception running to March 15, 2027. The clinical-stage company needs roughly $7.0 million more to reach the second quarter of 2027.
Key Events · Earnings and Guidance · MBRX
-
Going Concern Doubt Reiterated
Management states that $7.3 million of cash at September 30, 2026 is not sufficient to fund planned operations for at least one year, and that about $7.0 million of additional funding is needed to support MIRACLE and operations into the second quarter of 2027.
-
Nasdaq Panel Grants Limited Exception
On November 12, 2026, the Nasdaq Hearings Panel granted an exception requiring bid-price compliance until November 16, 2026 and compliance with all Nasdaq Listing Rules through March 15, 2027; failure would subject the stock to immediate delisting.
-
Nine-Month Loss and Cash Burn
Net loss was $27.0 million for the nine months ended September 30, 2026 versus $49.1 million a year earlier, while cash used in operations rose to $21.7 million from $17.4 million.
-
Warrant Overhang and Repricing
2,412,762 equity-classified warrants remain outstanding at a $10.20 weighted-average exercise price, and post-quarter ATM sales of 16,175 shares at $8.52–$8.72 lowered the Series I exercise price to $8.22.
Analysis · MBRX · Life Sciences
With $7.3 million in cash at the end of September, Moleculin says it cannot fund operations for a year and needs roughly $7.0 million more to carry the MIRACLE AML trial into the second quarter of 2027. There is no revenue and the accumulated deficit stands at $233.0 million, so the only path is more equity — and its ATM and Series I warrants are already repricing downward as shares are sold. The one piece of good news is procedural: on November 12, 2026, the Nasdaq Hearings Panel granted an exception giving the company until November 16, 2026 to regain bid-price compliance and requiring all other listing rules through March 15, 2027. That buys time but does not remove the delisting risk, and the Q1 2027 MIRACLE Part A readout is the event that will decide whether the company can raise money on acceptable terms.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $7.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $3.23 to $243.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.